Annual report pursuant to Section 13 and 15(d)

SIGNIFICANT CONCENTRATIONS (Details)

v3.3.1.900
SIGNIFICANT CONCENTRATIONS (Details) - USD ($)
12 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
SIGNIFICANT CONCENTRATIONS      
Accounts receivable $ 203,000 $ 5,750,000  
Sales [Member] | Customer Concentration Risk [Member] | Bristol-Myers Squibb Company      
SIGNIFICANT CONCENTRATIONS      
Concentration risk as a percentage of revenue 60.00%    
Sales [Member] | Customer Concentration Risk [Member] | Aclaris      
SIGNIFICANT CONCENTRATIONS      
Concentration risk as a percentage of revenue 28.00%    
Sales [Member] | Customer Concentration Risk [Member] | Novartis      
SIGNIFICANT CONCENTRATIONS      
Concentration risk as a percentage of revenue 12.00%    
Sales [Member] | Customer Concentration Risk [Member] | Astra Zeneca A B      
SIGNIFICANT CONCENTRATIONS      
Concentration risk as a percentage of revenue   100.00% 80.00%
Sales [Member] | Customer Concentration Risk [Member] | Daiichi Sankyo      
SIGNIFICANT CONCENTRATIONS      
Concentration risk as a percentage of revenue     20.00%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Bristol-Myers Squibb Company      
SIGNIFICANT CONCENTRATIONS      
Accounts receivable $ 203,000    
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Astra Zeneca A B      
SIGNIFICANT CONCENTRATIONS      
Accounts receivable   $ 5,800,000  
Accounts Receivable [Member] | Credit Concentration Risk [Member] | Bristol-Myers Squibb Company      
SIGNIFICANT CONCENTRATIONS      
Accounts receivable $ 203,000    
Accounts Receivable [Member] | Credit Concentration Risk [Member] | Astra Zeneca A B      
SIGNIFICANT CONCENTRATIONS      
Accounts receivable   $ 5,800,000